More recently, locked nucleic acid (LNA) gapmers have been used to achieve knockdown of DUX4 and show improvements in muscle fusion and structure in-vitro and efficient uptake and efficacy in-vivo further demonstrating the potential for AON therapy for FSHD [70]. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.